The pooled results also showed that patients with higher SNHG12 expression level were more exposed to worse clinicopathological outcomes including larger tumor size, higher Gleason score in prostate cancer, advanced TNM stage, higher WHO grade in glioma, LNM, and DM. Here, SNHG12 is linked to prostate carcinoma.